ALK-positive tumors are a clinically relevant subgroup as they can be very effectively treated with the ALK inhibitor crizotinib.
Os tumores ALK-positivos son un subgrupo clinicamente relevante, xa que poden ser tratados con moita efectividade co inhibidor de ALK crizotinib.